Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-84b7d79bbc-fnpn6 Total loading time: 0 Render date: 2024-07-27T22:50:21.820Z Has data issue: false hasContentIssue false

36 - Ovarian Germ Cell Tumors

from Section 5 - Gynecologic Oncology

Published online by Cambridge University Press:  01 February 2018

By
Kristin L. Bixel  and
Jeff Fowler
Edited by
Lisa Keder  and
Martin E. Olsen
Lisa Keder
Affiliation:
Ohio State University
Martin E. Olsen
Affiliation:
East Tennessee State University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Gynecologic Care , pp. 350 - 359
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blaustein, A, Kurman, RJ. Blaustein’s Pathology of the Female Genital Tract. 6th ed. New York: Springer; 2011. xv, 1246pp.Google Scholar
Talerman, A. Germ cell tumors of the ovary. Curr Opin Obstet Gynecol. 1997;9(1):44–7.CrossRefGoogle ScholarPubMed
Low, JJ, Ilancheran, A, Ng, JS. Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):347–55.Google Scholar
Gershenson, DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol. 1994;55(3 Pt 2):S62–72.CrossRefGoogle ScholarPubMed
Norris, HJ, Jensen, RD. Relative frequency of ovarian neoplasms in children and adolescents. Cancer. 1972;30(3):713–9.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
Smith, HO, Berwick, M, Verschraegen, CF. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–85.Google Scholar
Kurman, RJ, International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 pp.Google Scholar
Lin, KY, Bryant, S, Miller, DS, Kehoe, SM, Richardson, DL, Lea, JS. Malignant ovarian germ cell tumor: role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014;134(1):84–9.Google Scholar
Scully, RE. Gonadoblastoma: a review of 74 cases. Cancer. 1970;25(6):1340–56.3.0.CO;2-N>CrossRefGoogle ScholarPubMed
Matei, DE, Michael, H, Riussell, AH, Gershenson, DM. Ovarian germ cell tumors. In: Barakat, RR, Markman, M, Randall, ME, eds. Principles and Practice of Gynecologic Oncology, 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2009. p. 837–54.Google Scholar
Schellhas, HF. Malignant potential of the dysgenetic gonad. Part 1. Obstet Gynecol. 1974;44(2):298–309.Google ScholarPubMed
Young, RH. Ovarian tumors and tumor-like lesions in the first three decades. Sem Diag Pathol. 2014;31(5):382–426.CrossRefGoogle ScholarPubMed
Kurman, RJ, Norris, HJ. Malignant germ cell tumors of the ovary. Hum Pathol. 1977;8(5):551–64.CrossRefGoogle ScholarPubMed
Sever, M, Jones, TD, Roth, LM et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005;18(11):1411–16.CrossRefGoogle ScholarPubMed
Cheng, L, Thomas, A, Roth, LM, Zheng, W, Michael, H, Karim, FW. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28(10):1341–6.CrossRefGoogle ScholarPubMed
Hoei-Hansen, CE, Kraggerud, SM, Abeler, VM, Kaern, J, Rajpert-De Meyts, E, Lothe, RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007;6:12.Google Scholar
Nogales, FF, Preda, O, Nicolae, A. Yolk sac tumours revisited. A review of their many faces and names. Histopath. 2012;60(7):1023–33.Google Scholar
Kurman, RJ, Norris, HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer. 1976;38(6):2404–19.3.0.CO;2-3>CrossRefGoogle ScholarPubMed
McCluggage, WG, Young, RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol. 2005;22(1):3–32.CrossRefGoogle ScholarPubMed
Ramalingam, P, Malpica, A, Silva, EG, Gershenson, DM, Liu, JL, Deavers, MT. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004;28(11):1499–1505.CrossRefGoogle ScholarPubMed
Kurman, RJ, Norris, HJ. Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer. 1976;38(6):2420–33.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Kurman, RJ, Norris, HJ. Malignant mixed germ cell tumors of the ovary: a clinical and pathologic analysis of 30 cases. Obstet Gynecol. 1976;48(5):579–89.Google Scholar
Doss, N, Jr., Forney, JP, Vellios, F, Nalick, RH. Covert bilaterality of mature ovarian teratomas. Obstet Gynecol. 1977;50(6):651–3.Google ScholarPubMed
Ayhan, A, Aksu, T, Develioglu, O, Tuncer, ZS, Ayhan, A. Complications and bilaterality of mature ovarian teratomas (clinicopathological evaluation of 286 cases). Aust N Z J Obstet Gynaecol. 1991;31(1):83–5.CrossRefGoogle ScholarPubMed
Rim, SY, Kim, SM, Choi, HS. Malignant transformation of ovarian mature cystic teratoma. Int J Gynecol Cancer. 2006;16(1):140–4.Google Scholar
Westhoff, C, Pike, M, Vessey, M. Benign ovarian teratomas: a population-based case-control study. Br J Cancer. 1988;58(1):93–8.Google Scholar
Dos Santos, L, Mok, E, Iasonos, A et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol. 2007;105(2):321–4.CrossRefGoogle ScholarPubMed
Norris, HJ, Zirkin, HJ, Benson, WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer. 1976;37(5):2359–72.Google Scholar
O’Connor, DM, Norris, HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol. 1994;13(4):283–9.Google Scholar
De Backer, A, Madern, GC, Oosterhuis, JW, Hakvoort-Cammel, FG, Hazebroek, FW. Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer. 2006;46(4):459–64.CrossRefGoogle ScholarPubMed
Gershenson, DM, Del Junco, G, Copeland, LJ, Rutledge, FN. Mixed germ cell tumors of the ovary. Obstet Gynecol. 1984;64(2):200–206.Google ScholarPubMed
Tangjitgamol, S, Hanprasertpong, J, Manusirivithaya, S, Wootipoom, V, Thavaramara, T, Buhachat, R. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand. 2010;89(2):182–9.Google Scholar
Yang, C, Wang, S, Li, CC, Zhang, J, Kong, XR, Ouyang, J. Ovarian germ cell tumors in children: a 20-year retrospective study in a single institution. Eur J Gynaecol Oncol. 2011;32(3):289–92.Google ScholarPubMed
Panteli, C, Curry, J, Kiely, E et al. Ovarian germ cell tumours: a 17-year study in a single unit. Eur J Pediatr Surg. 2009;19(2):96–100.Google Scholar
Asadourian, LA, Taylor, HB. Dysgerminoma. An analysis of 105 cases. Obstet Gynecol. 1969;33(3):370–9.Google ScholarPubMed
Kodama, M, Grubbs, BH, Blake, EA et al. Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. Eur J Obstet Gynecol Repr Bio. 2014;181:145–56.Google ScholarPubMed
Pectasides, D, Pectasides, E, Kassanos, D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34(5):427–41.Google ScholarPubMed
Sekiya, S, Seki, K, Nagai, Y. Rise of serum CA 125 in patients with pure ovarian yolk sac tumors. Int J Gynaecol Obstet. 1997;58(3):323–4.Google Scholar
Levato, F, Martinello, R, Campobasso, C, Porto, S. LDH and LDH isoenzymes in ovarian dysgerminoma. Eur J Gynaecol Oncol. 1995;16(3):212–5.Google Scholar
Schwartz, PE, Morris, JM. Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol. 1988;72(3 Pt 2):511–5.Google Scholar
Gershenson, DM, Del Junco, G, Herson, J, Rutledge, FN. Endodermal sinus tumor of the ovary: the M. D. Anderson experience. Obstet Gynecol. 1983;61(2):194–202.Google Scholar
Talerman, A, Haije, WG, Baggerman, L. Serum alphafetoprotein (AFP) in diagnosis and management of endodermal sinus (yolk sac) tumor and mixed germ cell tumor of the ovary. Cancer. 1978;41(1):272–8.Google Scholar
Kawai, M, Furuhashi, Y, Kano, T et al. Alpha-fetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol. 1990;39(2):160–6.CrossRefGoogle ScholarPubMed
Konishi, I, Fujii, S, Okamura, H, Sakahara, H, Endo, K, Torizuka, K, et al. Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors: correlation between tumor markers and histological types of ovarian tumors. Nihon Sanka Fujinka Gakkai Zasshi. 1986;38(6):827–36.Google Scholar
Prat, J, Oncology FCoG. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–9.Google Scholar
Gershenson, DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938–43.CrossRefGoogle ScholarPubMed
Gershenson, DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005(34):43–7.Google Scholar
Low, JJ, Perrin, LC, Crandon, AJ, Hacker, NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89(2):391–8.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Schwartz, PE, Chambers, SK, Chambers, JT, Kohorn, E, McIntosh, S. Ovarian germ cell malignancies: the Yale University experience. Gynecol Oncol. 1992;45(1):26–31.Google Scholar
Perrin, LC, Low, J, Nicklin, JL, Ward, BG, Crandon, AJ. Fertility and ovarian function after conservative surgery for germ cell tumours of the ovary. Aust N Z J Obstet Gynaecol. 1999;39(2):243–5.Google Scholar
Slayton, RE, Park, RC, Silverberg, SG, Shingleton, H, Creasman, WT, Blessing, JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985;56(2):243–8.3.0.CO;2-T>CrossRefGoogle Scholar
Billmire, D, Vinocur, C, Rescorla, F et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004;39(3):424–9 (9).Google Scholar
Ertas, IE, Taskin, S, Goklu, R et al. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors. J Obstet Gynaecol Res. 2014;40(3):797–805.Google Scholar
Park, JY, Kim, DY, Suh, DS et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors. Gynecol Oncol. 2015;137(3):418–22.CrossRefGoogle ScholarPubMed
Yoo, SC, Kim, WY, Yoon, JH, Chang, SJ, Chang, KH, Ryu, HS. Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy. Acta Obstet Gynecol Scand. 2010;89(1):126–30.Google Scholar
Billmire, DF. Malignant germ cell tumors in childhood. Semin Pediatr Surg. 2006;15(1):30–6.CrossRefGoogle ScholarPubMed
Williams, SD, Blessing, JA, Moore, DH, Homesley, HD, Adcock, L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Int Med. 1989;111(1):22–7.CrossRefGoogle ScholarPubMed
Bafna, UD, Umadevi, K, Kumaran, C, Nagarathna, DS, Shashikala, P, Tanseem, R. Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer. 2001;11(4):300–304.CrossRefGoogle Scholar
Williams, SD, Blessing, JA, DiSaia, PJ, Major, FJ, Ball, HG III, Liao, SY. Second-look laparotomy in ovarian germ cell tumors: the Gynecologic Oncology Group experience. Gynecol Oncol. 1994;52(3):287–91.Google Scholar
Gershenson, DM. Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors. Semin Surg Oncol. 1994;10(4):290–8.Google Scholar
Billmire, DF, Cullen, JW, Rescorla, FJ et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol. 2014;32(5):465–70.CrossRefGoogle Scholar
Dark, GG, Bower, M, Newlands, ES, Paradinas, F, Rustin, GJ. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol. 1997;15(2):620–4.Google Scholar
Patterson, DM, Murugaesu, N, Holden, L, Seckl, MJ, Rustin, GJ. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43–50.Google Scholar
Mangili, G, Sigismondi, C, Lorusso, D, Pignata, S. Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. J Clin Oncol. 2014;32(25):2814–5.Google Scholar
Gershenson, DM, Morris, M, Cangir, A et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990;8(4):715–20.CrossRefGoogle ScholarPubMed
Williams, S, Blessing, JA, Liao, SY, Ball, H, Hanjani, P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12(4):701–6.Google Scholar
Mann, JR, Raafat, F, Robinson, K et al. The United Kingdom Children’s Cancer Study Group’s second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000;18(22):3809–18.CrossRefGoogle ScholarPubMed
Doi, M, Okamoto, Y, Yamauchi, M, Naitou, H, Shinozaki, K. Bleomycin-induced pulmonary fibrosis after tumor lysis syndrome in a case of advanced yolk sac tumor treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy. Int J Clin Oncol. 2012;17(5):528–31.Google Scholar
O’Sullivan, JM, Huddart, RA, Norman, AR, Nicholls, J, Dearnaley, DP, Horwich, A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–6.Google Scholar
Usman, M, Faruqui, ZS, ud Din, N, Zahid, KF. Bleomycin induced pulmonary toxicity in patients with germ cell tumours. J Ayub Med Coll Abbottabad. 2010;22(3):35–7.Google Scholar
Buskirk, SJ, Schray, MF, Podratz, KC et al. Ovarian dysgerminoma: a retrospective analysis of results of treatment, sites of treatment failure, and radiosensitivity. Mayo Clin Proc. 1987;62(12):1149–57.Google Scholar
Mangili, G, Sigismondi, C, Gadducci, A et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer. 2011;21(8):1414–21.Google Scholar
Murugaesu, N, Schmid, P, Dancey, G et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol: Offic J Am Soc Clin Oncol. 2006;24(30):4862–6.Google Scholar
Solheim, O, Gershenson, DM, Trope, CG et al. Prognostic factors in malignant ovarian germ cell tumours (the surveillance, epidemiology and end results experience 1978–2010). Euro J Cancer. 2014;50(11):1942–50.Google Scholar
Weinberg, LE, Lurain, JR, Singh, DK, Schink, JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol. 2011;121(2):285–9.CrossRefGoogle ScholarPubMed
Loren, AW, Mangu, PB, Beck, LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–2510.Google Scholar
Simone, CG, Markham, MJ, Dizon, DS. Chemotherapy in ovarian germ cell tumors: a systematic review. Gynecol Oncol. 2016;141(3):602–607.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×